MedTrace Logo

ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

NCT00439192 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2007-08-08

No results posted yet for this study

Summary

This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.

Conditions

Interventions

DRUG

ELB245

DRUG

Tolterodine

Sponsors & Collaborators

  • elbion AG

    lead INDUSTRY

Principal Investigators

  • Martin Michel, Prof. · Dept. Pharmacology & Pharmacotherapy, AMC, University of Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Completion
2007-08-31

Countries

  • Germany
  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439192 on ClinicalTrials.gov